Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|March 27, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-04-05-2017
- Volume 12
- Issue 4
Permira Funds to Acquire LSNE
Author(s)Pharmaceutical Technology Editors
Permira will acquire LSNE, a CDMO for the pharmaceutical and medical device markets.
Advertisement
Permira, the global private equity firm, announced on March 27, 2017 that a company backed by the Permira funds has signed a definitive agreement to acquire Lyophilization Services of New England, Inc (LSNE), a contract development and manufacturing organization for the pharmaceutical and medical device markets, in partnership with management. As part of the transaction, LSNE Founder and Chief Executive Officer Matt Halvorsen will maintain a significant equity stake in the company and will continue to lead the company in his current role.
In conjunction with the transaction, Claes Glassell, the former CEO of CMC Biologics and a 30-year pharmaceutical industry veteran, will join as chairman of the board of LSNE in support of the management team and growth strategy. The Permira funds’ investment will support the company’s growth, including expanding the company’s capacity and address commercial-stage opportunities, extending its capabilities in manufacturing and development services, and pursuing selective acquisitions.
Source:
Articles in this issue
over 9 years ago
Seeking Solutions for Oral Delivery of Biologic APIsover 9 years ago
Should More Pharma Products be Made in the USA?over 9 years ago
Technology to the Rescue for Data Integrity Challenges?over 9 years ago
Putting GS1’s EPCIS Standards to the Testover 9 years ago
RSSL Expands Particle Characterization Capabilitiesover 9 years ago
Butterworth Laboratories Expands UK Lab Operationsover 9 years ago
Eurofins Scientific Invests in New UK Facilityover 9 years ago
Hitachi Chemical Purchases PCT From Caladrius Biosciencesover 9 years ago
JRS Pharma Adds Povidone Product LineAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5